Vanda Pharmaceuticals (VNDA) Expected to Announce Quarterly Earnings on Wednesday

Vanda Pharmaceuticals (NASDAQ:VNDA) is anticipated to post its Q4 2025 results after the market closes on Wednesday, February 11th. Analysts expect Vanda Pharmaceuticals to post earnings of ($1.45) per share and revenue of $59.2750 million for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, February 11, 2026 at 4:30 PM ET.

Vanda Pharmaceuticals Trading Down 0.8%

NASDAQ:VNDA opened at $7.51 on Tuesday. The company has a 50-day moving average price of $7.23 and a 200-day moving average price of $5.64. The stock has a market cap of $443.84 million, a price-to-earnings ratio of -5.29 and a beta of 0.62. The company has a current ratio of 3.12, a quick ratio of 3.10 and a debt-to-equity ratio of 0.01. Vanda Pharmaceuticals has a 12 month low of $3.81 and a 12 month high of $9.60.

Institutional Trading of Vanda Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Royal Bank of Canada raised its stake in Vanda Pharmaceuticals by 34.3% during the first quarter. Royal Bank of Canada now owns 55,713 shares of the biopharmaceutical company’s stock valued at $256,000 after buying an additional 14,232 shares during the last quarter. Millennium Management LLC increased its holdings in shares of Vanda Pharmaceuticals by 220.0% during the first quarter. Millennium Management LLC now owns 2,139,591 shares of the biopharmaceutical company’s stock valued at $9,821,000 after acquiring an additional 1,470,898 shares in the last quarter. Hsbc Holdings PLC increased its holdings in shares of Vanda Pharmaceuticals by 17.6% during the second quarter. Hsbc Holdings PLC now owns 66,554 shares of the biopharmaceutical company’s stock valued at $319,000 after acquiring an additional 9,960 shares in the last quarter. Norges Bank purchased a new position in shares of Vanda Pharmaceuticals in the 2nd quarter worth about $543,000. Finally, Walleye Capital LLC boosted its stake in Vanda Pharmaceuticals by 155.1% in the 2nd quarter. Walleye Capital LLC now owns 94,298 shares of the biopharmaceutical company’s stock worth $445,000 after purchasing an additional 57,332 shares in the last quarter. Hedge funds and other institutional investors own 88.14% of the company’s stock.

Analysts Set New Price Targets

Several analysts have commented on VNDA shares. Cantor Fitzgerald restated an “overweight” rating on shares of Vanda Pharmaceuticals in a report on Wednesday, December 17th. Jefferies Financial Group upped their target price on Vanda Pharmaceuticals from $5.00 to $7.50 and gave the stock a “hold” rating in a report on Wednesday, December 31st. UBS Group restated a “buy” rating on shares of Vanda Pharmaceuticals in a research note on Monday, January 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research report on Wednesday, January 21st. Finally, B. Riley Financial increased their price objective on Vanda Pharmaceuticals from $11.00 to $14.00 and gave the stock a “buy” rating in a report on Wednesday, December 31st. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $13.63.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.